Gennifer MckeeGennifer Mckee
|
 |
The patient developed choreiformmovements ortho evra that persisted despite obtundation pain treatment and attempts to extinguish themwith naloxone, morphine, and diazepam. Thistranslates to identifying between 5 and 1116 patients for individual CS-PURE ina 500 000-member health plan. In later years there has been a marked increase in the number of bloodsamples testing positive for Carisoprodol ( Soma ) or meprobamate (the major metabolite).MATERIAL AND ortho evra METHODS. 480 cases testing positive for central muscle relaxants inthe years 1984-1998 were further studied. We developed and empiricallyvalidated a group of plan-b queries using CS-PURE to identify patients with potentialcontrolled substance misuse or mismanagement that would warrant furtherevaluation by the treating physician, a quality assurance function, or ultram generic tretinoin themedical director. Claims-based CS-PURE identification levetiracetam is generalizable to mosthealth insurers with access to medical and pharmaceutical claims records.Although CS-PURE are not direct measures of misuse, they can direct attention topotential problems to determine if intervention is needed. Thisknowledge should have implications for doctors prescribing centrally actingmuscle relaxants.. STUDY aripiprazole DESIGN:Retrospective validation of the system using insurance claims. Compared with blood samplespositive primarily for benzodiazepines, there were more women in the group (39%vs. Thirty-four CS-PURE querieswere developed in SAS aripiprazole and applied to administrative claims records to identifypatients with potential controlled substance misuse or mismanagement. Carbidopa-levodopa overdose.A 57-year-old woman ingested 15 to 17 tablets of carbidopa-levodopa 10/100tablets (carbidopa 150 mg and levodopa 1,500 mg) along with ibuprofen,Carisoprodol ( Soma ), hydrocodone, and acetaminophen. 15%), and fewer drugs and less alcohol were detected. Thepositive samples may indicate misuse or abuse due to the fact that high drugconcentrations and concomitant use of benzodiazepines were frequent. To develop a systems approach to identify, for further evaluation,patients with potential controlled substance misuse or mismanagement usingsoftware queries applied to administrative health claims data. She required paralysis for 60 hours, when her chorearesolved. The only drug inthis group now marketed in Norway is Carisoprodol ( Soma ). Fromthese, we identified 10 CS-PURE with the highest expert agreement thatintervention was warranted. Data from administrative health claims databases representing nearly 7million individuals younger than 65 years were used by multidisciplinary expertpanels to develop and validate controlled substance patterns of utilizationrequiring evaluation (CS-PURE) criteria. The National Institute ofForensic Toxicology in Norway analyses all blood samples from suspected druggeddrivers. The prevalence rates for CS-PURE ranged from 0.001% to 0.252%. Centrally acting muscle relaxants and traffic hazardsAn increasing number of the centrally acting muscle relaxants werewithdrawn from the Norwegian market during the 1988-98 period. When the patient developed a rising levelof creatine phosphokinase and myoglobinuria, she was treated with ventilatorysupport and pancuronium. Expert panel agree, ment that CS-PURE correctlyidentified cases ranged from 48% to 100%, with at least 50% agreement in 9 of 10CS-PURE. Carisoprodol ( Soma ) intoxications and serotonergic features.OBJECTIVES.
|